Articles

June 24, 2025
Smart manufacturing is “nearly universal” with 95% of manufacturers saying they are using or evaluating smart technology, according to a new survey from Rockwell Automation.
June 23, 2025
The CDMO completed site construction and infrastructure installation at its 50,000-square-foot facility, with full-scale GMP production slated for this summer.
June 20, 2025
While the process has been a buzzword for years, offering an alternative to traditional batch manufacturing, industry uptake has been slow. However, the tide may be turning.
June 18, 2025
CDMOs face shifting demand, tighter regulations, and growing complexity in sterile injectable supply chains.
June 17, 2025
While the pharmaceutical industry has been slow to adopt continuous manufacturing, it appears to be gaining momentum.
June 16, 2025
U.S. Pharmacopeia CEO Ronald Piervincenzi told lawmakers that advanced manufacturing technologies will better enable production of pharmaceuticals and pharma ingredients.
June 13, 2025
The Tar Heel State’s decades-long focus on economic development in life sciences and pharma manufacturing is bearing fruit, as it looks to rival the Bay Area and Boston.
June 12, 2025
Part of Danaher Corporation, Cytiva’s strategic investment in Asia-Pacific, Europe, and the United States aligns with its long-term growth plan to better serve customers.
June 11, 2025
While Big Pharma companies have announced $270 billion in domestic investments, lab leasing declined significantly in Q1 2025, finds JLL’s U.S. Life Sciences Property Report.
June 10, 2025
Equipped with high-speed lines, robotics, and automated systems, the site started commercial production at the end of 2024 after completing construction in only two years.
June 9, 2025
The CDMO is building identical large-scale production facilities in the U.S. and Denmark, designed to modularly and seamlessly integrate manufacturing regardless of location.
June 6, 2025
The company is expanding the site’s sterile fill-finish capabilities while sunsetting traditional batch, solid dose production and adopting continuous manufacturing.
June 2, 2025
Despite the potential threat of tariffs, trade policy did not factor into the India-based CRDMO’s purchase of a Baltimore biologics site from Emergent BioSolutions.
May 30, 2025
More than 300 comments have been posted in response to a Department of Commerce investigation into the importation of certain pharmaceuticals and pharma ingredients.
May 29, 2025
CEO Padraig McDonnell contends that Biovectra’s capabilities are in the “sweet spot” of GLP-1s and complex chemistries, with strong medium- and long-term growth potential.
May 28, 2025
As labs look to overcome longstanding challenges in achieving bioanalytical excellence, many are turning to digital technologies.
May 27, 2025
The Minnesota-based company is now being covered by William Blair analyst Max Smock who spoke with Pharma Manufacturing about Lifecore’s position in the CDMO landscape.
May 23, 2025
The spin-off is meant to improve operational focus and address concerns raised by its CDMO customers about potential conflicts of interest.
May 23, 2025
The threat of tariffs on pharmaceuticals and “most favored nation” drug pricing are weighing on the sector as biotech funding continues to dry up.
May 19, 2025
With a record number of FDA biosimilar approvals in 2024, CMOs specializing in biologics can expect to see higher biosimilar volumes, according to GlobalData.
May 16, 2025
PhRMA warned that President Trump’s executive order on most favored nation would jeopardize hundreds of billions of dollars in planned U.S. investments by its members.
May 14, 2025
The company warned that if the executive order goes into effect, Roche’s ability to invest $50 billion in its U.S. R&D and manufacturing sites will be in question.
May 13, 2025
CEO Bill Anderson said that the company has “considerable” production capabilities in both the U.S. and Europe but has no immediate plans to shift them.
May 9, 2025
CEO Christophe Weber said that the investment is not a new strategy and reflects the position of the U.S. as the world’s leading market for biopharma innovation.
May 8, 2025
Combined, the company projects these efforts will generate $43 billion in economic impact over the next five years.
May 6, 2025
The announcement comes after President Trump signed an executive order aimed at expediting the approval process for domestic pharmaceutical manufacturing facilities.
May 5, 2025
Expansions at sites in Le Mans and Mourenx, France have solidified the CDMO’s position in targeting the hot antibody-drug conjugate and peptide purification markets.
May 2, 2025
Dave Ricks said Lilly supports the administration’s goal of bringing pharma manufacturing back to the U.S. but doesn’t see tariffs as the “right mechanism” for reshoring.
April 30, 2025
CEO Albert Bourla said that President Trump’s threat of pharmaceutical tariffs is deterring the company from further investing in U.S. manufacturing and R&D.
April 28, 2025
CEO Rob Michael told analysts that the company is investing more than $10 billion in the U.S. to support volume growth and expansion into new areas such as obesity.